DOCSLIB.ORG

Activation Tyrosine Kinases, Btk and Lyn, in Mast Cell Redundant And

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Activation Tyrosine Kinases, Btk and Lyn, in Mast Cell Redundant And Redundant and Opposing Functions of Two Tyrosine Kinases, Btk and Lyn, in Mast Cell Activation This information is current as Yuko Kawakami, Jiro Kitaura, Anne B. Satterthwaite, of September 25, 2021. Roberta M. Kato, Koichi Asai, Stephen E. Hartman, Mari Maeda-Yamamoto, Clifford A. Lowell, David J. Rawlings, Owen N. Witte and Toshiaki Kawakami J Immunol 2000; 165:1210-1219; ; doi: 10.4049/jimmunol.165.3.1210 Downloaded from http://www.jimmunol.org/content/165/3/1210 References This article cites 75 articles, 45 of which you can access for free at: http://www.jimmunol.org/content/165/3/1210.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 25, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2000 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Redundant and Opposing Functions of Two Tyrosine Kinases, Btk and Lyn, in Mast Cell Activation1 Yuko Kawakami,* Jiro Kitaura,* Anne B. Satterthwaite,† Roberta M. Kato,‡ Koichi Asai,* Stephen E. Hartman,* Mari Maeda-Yamamoto,§ Clifford A. Lowell,¶ David J. Rawlings,‡ Owen N. Witte,†ʈ and Toshiaki Kawakami2* Protein-tyrosine kinases play crucial roles in mast cell activation through the high-affinity IgE receptor (Fc⑀RI). In this study, we have made the following observations on growth properties and Fc⑀RI-mediated signal transduction of primary cultured mast cells from Btk-, Lyn-, and Btk/Lyn-deficient mice. First, Lyn deficiency partially reversed the survival effect of Btk deficiency. Second, Fc⑀RI-induced degranulation and leukotriene release were almost abrogated in Btk/Lyn doubly deficient mast cells while singly deficient cells exhibited normal responses. Tyrosine phosphorylation of cellular proteins including phospholipases C-␥1 and C-␥2 was reduced in Btk/Lyn-deficient mast cells. Accordingly, Fc⑀RI-induced elevation of intracellular Ca2؉ concentrations and Downloaded from activation of protein kinase Cs were blunted in the doubly deficient cells. Third, in contrast, Btk and Lyn demonstrated opposing roles in cytokine secretion and mitogen-activated protein kinase activation. Lyn-deficient cells exhibited enhanced secretion of TNF-␣ and IL-2 apparently through the prolonged activation of extracellular signal-related kinases and c-Jun N-terminal kinase. Potentially accounting for this phenomenon and robust degranulation in Lyn-deficient cells, the activities of protein kinase C␣ and protein kinase C␤II, low at basal levels, were enhanced in these cells. Fourth, cytokine secretion was severely reduced and c-Jun http://www.jimmunol.org/ N-terminal kinase activation was completely abrogated in Btk/Lyn-deficient mast cells. The data together demonstrate that Btk and Lyn are involved in mast cell signaling pathways in distinctly different ways, emphasizing that multiple signal outcomes must be evaluated to fully understand the functional interactions of individual signaling components. The Journal of Immunology, 2000, 165: 1210–1219. ross-linking of IgE-bound high-affinity IgE receptors the ␤ subunit in resting cells through interaction of the N-terminal (Fc⑀RI)3 on mast cells by Ag leads to the activation of unique region of Lyn with the C-terminal cytoplasmic domain of C mast cells culminating in the release of a panel of proin- the ␤ subunit (3, 4). Lyn is activated by transphosphorylation upon flammatory mediators. Mast cell activation triggers reactions of Fc⑀RI cross-linking (5). Activated Lyn phosphorylates the tyrosine by guest on September 25, 2021 immediate hypersensitivity (1). Fc⑀RI is composed of an IgE-bind- residues in the immunoreceptor tyrosine-based activation motifs ing ␣ subunit, a four-transmembrane, signal-amplifying ␤ subunit, (ITAM) of the cytoplasmic regions of the ␤ and ␥ subunits (6). and a disulfide-bonded pair of ␥ subunits (reviewed in Ref. 2). The Phosphorylated ITAMs of the ␤ and ␥ subunits recruit Lyn and Src family protein tyrosine kinase (PTK) Lyn is associated with Syk, respectively, through Src homology (SH) 2-phosphotyrosine interactions (7–9). Newly recruited PTKs are activated by transphosphorylation of tyrosine residues in their activation loops *Division of Allergy, La Jolla Institute for Allergy and Immunology, San Diego, CA and by conformational changes in the case of Syk (10, 11). Active 92121; †Department of Microbiology and Molecular Genetics, University of Califor- nia, Los Angeles, CA 90095; ‡Department of Pediatrics, University of California, Los Lyn and Syk phosphorylate themselves and other protein sub- Angeles, CA 90095; §National Research Institute of Vegetables, Ornamental Plants strates such as phospholipase C (PLC)-␥1 and -␥2 (12–14). Acti- and Tea, Kanaya, Shizuoka, Japan; ¶Department of Laboratory Medicine, University ʈ vation of PLC leads to the generation of two second messengers, of California, San Francisco, CA 94143; and Howard Hughes Medical Institute, University of California, Los Angeles, CA 90095 inositol 1,4,5-trisphosphate (IP3) and diacylglycerol. IP3 mobilizes 2ϩ Received for publication November 11, 1999. Accepted for publication May 9, 2000. Ca from intracellular storage sites, and diacylglycerol together 2ϩ The costs of publication of this article were defrayed in part by the payment of page with Ca activates protein kinase C (PKC) (reviewed in Ref. 15). ϩ charges. This article must therefore be hereby marked advertisement in accordance Both Ca2 and PKC appear to be required for optimal mast cell with 18 U.S.C. Section 1734 solely to indicate this fact. degranulation (16). 1 This work was supported in part by National Institutes of Health Grant AI42244, Bruton’s tyrosine kinase (Btk) is a member of the Tec family of AI33617, and AI38348 (to T.K.). A.B.S. is a Special Fellow of the Leukemia Society of America. D.J.R. is a recipient of a McDonnell Scholar Award and is supported in kinases characterized by N-terminal pleckstrin homology (PH) and part by the facilities of the Jonsson Comprehensive Cancer Center, University of Tec homology domains (17–19). btk mutations affect B cell de- California Los Angeles. O.N.W. is an Investigator of the Howard Hughes Medical velopment and result in X-linked agammaglobulinemia in humans Institute. This article is Publication No. 286 from the La Jolla Institute for Allergy and Immunology. (17, 18) and X-linked immunodeficiency (xid) in mice (20, 21). 2 Address correspondence and reprint requests to Dr. Toshiaki Kawakami, La Jolla Btk is also highly expressed in mast cells and is required for cy- Institute for Allergy and Immunology, 10355 Science Center Drive, San Diego, CA tokine production in response to Fc⑀RI cross-linking (22). Unlike 92121. E-mail address: [email protected] B cells, mast cell development does not require Btk. This suggests 3 ⑀ The abbreviations used are: Fc RI, high-affinity IgE receptor; Btk, Bruton’s tyrosine redundant roles for Btk and other Tec family kinases, such as kinase; DNP, dinitrophenyl; HSA, human serum albumin; IP3, inositol 1,4,5-trisphos- phate; MAP, mitogen-activated protein; PKC, protein kinase C; PLC, phospholipase Itk/Emt, in some mast cell signaling pathways. Mechanistically, C; PTK, protein-tyrosine kinase; SH, Src homology; ITAM, immunoreceptor ty- btk mutations result in the loss of extracellular Ca2ϩ influx and the rosine-based activation motif; PH, pleckstrin homology; BCR, B cell receptor; PI3-K, 2ϩ phosphatidylinositol 3-kinase; JNK, c-Jun N-terminal kinase; ERK, extracellular sig- sustained phase of Ca response in B cell receptor (BCR)-stim- nal-related kinase. ulated B cells (23, 24). This defective response may be due in part Copyright © 2000 by The American Association of Immunologists 0022-1767/00/$02.00 The Journal of Immunology 1211 to reduced PLC-␥ activation. Downstream of these early activation Biolabs (Boston, MA). Pansorbin was purchased from Calbiochem (La events in mast cells and B cells, Btk mediates the activation of Jolla, CA). Other chemicals of highest grade were obtained from Sigma JNK1, JNK2, and, to a lesser extent, p38 (25). JNK regulates c-Jun (St. Louis, MO), unless otherwise mentioned. and other transcription factors that induce the transcription of Cells TNF-␣, IL-2, and other cytokine genes (26), accounting for the btkϪ/Ϫ and lynϪ/Ϫ mice, each on a mixed C57BL/6 ϫ 129/Sv genetic reduced cytokine production in Btk-deficient mast cells. ϩ/Ϫ ϩ/Ϫ background, were mated to generate btk lyn F1 progeny. These F1 Activation of Btk in BCR and Fc⑀RI signaling systems requires mice were mated to obtain wild-type, btkϪ/Ϫ, lynϪ/Ϫ, and btkϪ/ϪlynϪ/Ϫ both phosphatidylinositol 3-kinase (PI3-K) and Src family kinases mice (36). Genotyping was done by Southern blotting or PCR analysis of (27, 28). The product of PI3-K, phosphatidylinositol 3,4,5- mouse tail-derived DNAs. Mast cells were cultured as described previously trisphosphate, is believed to recruit Btk to the plasma membrane (44). Briefly, bone marrow cells derived from the femur of the 6- to 10- wk-old mice were cultured in RPMI 1640 medium supplemented with 10% (29), where it is phosphorylated on tyrosine 551 in its activation FCS, 100 ␮M nonessential amino acids, 50 ␮M 2-ME, and 8% conditioned loop by activated Lyn molecules (27). Btk phosphorylated on ty- medium of IL-3 gene-transfected cells (bone marrow-derived mast cell rosine 551 is enzymatically active and autophosphorylates tyrosine medium).
Load more

Recommended publications
  • Calycosin Down-Regulates C-Met to Suppress Development of Glioblastomas
    J Biosci (2019) 44:96 Ó Indian Academy of Sciences DOI: 10.1007/s12038-019-9904-4 (0123456789().,-volV)(0123456789().,-volV) Calycosin down-regulates c-Met to suppress development of glioblastomas , XIAOHU NIE ,YUE ZHOU* ,XIAOBING LI,JIE XU,XUYAN PAN,RUI YIN and BIN LU Department of Neurosurgery, Huzhou Central Hospital, Huzhou, Zhejiang, People’s Republic of China *Corresponding author (Email, [email protected]) These authors contributed equally to this work. MS received 15 October 2018; accepted 9 June 2019; published online 7 August 2019 The antitumor effect of calycosin has been widely studied, but the targets of calycosin against glioblastomas are still unclear. In this study we focused on revealing c-Met as a potential target of calycosin suppressing glioblastomas. In this study, suppressed-cell proliferation and cell invasion together with induced-cell apoptosis appeared in calycosin-treated U251 and U87 cells. Under treatment of calycosin, the mRNA expression levels of Dtk, c-Met, Lyn and PYK2 were observed in U87 cells. Meanwhile a western blot assay showed that c-Met together with matrix metalloproteinases-9 (MMP9) and phosphorylation of the serine/threonine kinase AKT (p-AKT) was significantly down-regulated by calycosin. Furthermore, overexpressed c-Met in U87 enhanced the expression level of MMP9 and p-AKT and also improved cell invasion. Additionally, the expression levels of c-Met, MMP9 and p-AKT were inhibited by calycosin in c-Met overex- pressed cells. However, an AKT inhibitor (LY294002) only effected on MMP9 and p-AKT, not on c-Met. These data collectively indicated that calycosin possibility targeting on c-Met and exert an anti-tumor role via MMP9 and AKT.
    [Show full text]
  • Inhibition of DDR1-BCR Signalling by Nilotinib As a New Therapeutic
    Inhibition of DDR1-BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer Maya Jeitany, Cédric Leroy, Priscillia Tosti, Marie Lafitte, Jordy Le Guet, Valérie Simon, Debora Bonenfant, Bruno Robert, Fanny Grillet, Caroline Mollevi, et al. To cite this version: Maya Jeitany, Cédric Leroy, Priscillia Tosti, Marie Lafitte, Jordy Le Guet, et al.. Inhibition of DDR1- BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer. EMBO Molecular Medicine, Wiley Open Access, 2018, 10 (4), pp.e7918. 10.15252/emmm.201707918. hal- 01872978 HAL Id: hal-01872978 https://hal.archives-ouvertes.fr/hal-01872978 Submitted on 12 Jan 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution| 4.0 International License Research Article Inhibition of DDR1-BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer Maya Jeitany1,†, Cédric Leroy1,2,3,†, Priscillia Tosti1,†, Marie Lafitte1, Jordy Le Guet1, Valérie Simon1, Debora Bonenfant2, Bruno Robert4, Fanny Grillet5, Caroline Mollevi4, Safia El Messaoudi4, Amaëlle Otandault4, Lucile Canterel-Thouennon4, Muriel Busson4, Alain R Thierry4, Pierre Martineau4, Julie Pannequin5, Serge Roche1,*,† & Audrey Sirvent1,†,** Abstract The current clinical management involves surgical removal of the primary tumour, often associated with chemotherapy.
    [Show full text]
  • Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors
    Published OnlineFirst June 13, 2011; DOI: 10.1158/1078-0432.CCR-10-2616 Clinical Cancer Molecular Pathways Research Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors Juan Carlos Montero1, Samuel Seoane1, Alberto Ocaña2,3, and Atanasio Pandiella1 Abstract Dasatinib is a small molecule tyrosine kinase inhibitor that targets a wide variety of tyrosine kinases implicated in the pathophysiology of several neoplasias. Among the most sensitive dasatinib targets are ABL, the SRC family kinases (SRC, LCK, HCK, FYN, YES, FGR, BLK, LYN, and FRK), and the receptor tyrosine kinases c-KIT, platelet-derived growth factor receptor (PDGFR) a and b, discoidin domain receptor 1 (DDR1), c-FMS, and ephrin receptors. Dasatinib inhibits cell duplication, migration, and invasion, and it triggers apoptosis of tumoral cells. As a consequence, dasatinib reduces tumoral mass and decreases the metastatic dissemination of tumoral cells. Dasatinib also acts on the tumoral microenvironment, which is particularly important in the bone, where dasatinib inhibits osteoclastic activity and favors osteogenesis, exerting a bone-protecting effect. Several preclinical studies have shown that dasatinib potentiates the antitumoral action of various drugs used in the oncology clinic, paving the way for the initiation of clinical trials of dasatinib in combination with standard-of-care treatments for the therapy of various neoplasias. Trials using combinations of dasatinib with ErbB/HER receptor antagonists are being explored in breast, head and neck, and colorectal cancers. In hormone receptor–positive breast cancer, trials using combina- tions of dasatinib with antihormonal therapies are ongoing. Dasatinib combinations with chemother- apeutic agents are also under development in prostate cancer (dasatinib plus docetaxel), melanoma (dasatinib plus dacarbazine), and colorectal cancer (dasatinib plus oxaliplatin plus capecitabine).
    [Show full text]
  • Receptor Signaling and Syk in the Initiation of B-Cell Antigen
    Nonredundant Roles of Src-Family Kinases and Syk in the Initiation of B-Cell Antigen Receptor Signaling This information is current as Ondrej Stepanek, Peter Draber, Ales Drobek, Vaclav Horejsi of September 30, 2021. and Tomas Brdicka J Immunol 2013; 190:1807-1818; Prepublished online 18 January 2013; doi: 10.4049/jimmunol.1202401 http://www.jimmunol.org/content/190/4/1807 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2013/01/18/jimmunol.120240 Material 1.DC1 http://www.jimmunol.org/ References This article cites 75 articles, 32 of which you can access for free at: http://www.jimmunol.org/content/190/4/1807.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 30, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Nonredundant Roles of Src-Family Kinases and Syk in the Initiation of B-Cell Antigen Receptor Signaling Ondrej Stepanek, Peter Draber, Ales Drobek, Vaclav Horejsi, and Tomas Brdicka When a BCR on a mature B cell is engaged by its ligand, the cell becomes activated, and the Ab-mediated immune response can be triggered.
    [Show full text]
  • Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia
    cancers Review Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia Kalpana K. Bhanumathy 1,*, Amrutha Balagopal 1, Frederick S. Vizeacoumar 2 , Franco J. Vizeacoumar 1,3, Andrew Freywald 2 and Vincenzo Giambra 4,* 1 Division of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada; [email protected] (A.B.); [email protected] (F.J.V.) 2 Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada; [email protected] (F.S.V.); [email protected] (A.F.) 3 Cancer Research Department, Saskatchewan Cancer Agency, 107 Wiggins Road, Saskatoon, SK S7N 5E5, Canada 4 Institute for Stem Cell Biology, Regenerative Medicine and Innovative Therapies (ISBReMIT), Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, FG, Italy * Correspondence: [email protected] (K.K.B.); [email protected] (V.G.); Tel.: +1-(306)-716-7456 (K.K.B.); +39-0882-416574 (V.G.) Simple Summary: Protein phosphorylation is a key regulatory mechanism that controls a wide variety of cellular responses. This process is catalysed by the members of the protein kinase su- perfamily that are classified into two main families based on their ability to phosphorylate either tyrosine or serine and threonine residues in their substrates. Massive research efforts have been invested in dissecting the functions of tyrosine kinases, revealing their importance in the initiation and progression of human malignancies. Based on these investigations, numerous tyrosine kinase inhibitors have been included in clinical protocols and proved to be effective in targeted therapies for various haematological malignancies.
    [Show full text]
  • Beyond TCR Signaling: Emerging Functions of Lck in Cancer and Immunotherapy
    Review Beyond TCR Signaling: Emerging Functions of Lck in Cancer and Immunotherapy Ursula Bommhardt, Burkhart Schraven and Luca Simeoni * Institute of Molecular and Clinical Immunology, Otto-von-Guericke University, Leipziger Strasse 44, 39120 Magdeburg, Germany * Correspondence: [email protected]; Tel. +49-391-6717894 Received: 12 June 2019; Accepted: 12 July 2019; Published: 16 July 2019 Abstract: In recent years, the lymphocyte-specific protein tyrosine kinase (Lck) has emerged as one of the key molecules regulating T-cell functions. Studies using Lck knock-out mice or Lck-deficient T-cell lines have shown that Lck regulates the initiation of TCR signaling, T-cell development, and T-cell homeostasis. Because of the crucial role of Lck in T-cell responses, strategies have been employed to redirect Lck activity to improve the efficacy of chimeric antigen receptors (CARs) and to potentiate T-cell responses in cancer immunotherapy. In addition to the well-studied role of Lck in T cells, evidence has been accumulated suggesting that Lck is also expressed in the brain and in tumor cells, where it actively takes part in signaling processes regulating cellular functions like proliferation, survival and memory. Therefore, Lck has emerged as a novel druggable target molecule for the treatment of cancer and neuronal diseases. In this review, we will focus on these new functions of Lck. Keywords: Lck; T cell; CAR; cancer; leukemia; brain 1. Introduction The lymphocyte-specific protein tyrosine kinase (Lck) is a member of the Src family of protein tyrosine kinases firstly identified in the 1980s [1,2]. Since then, the function of Lck has been extensively investigated and many mechanistic insights into the regulation of its activity have been revealed.
    [Show full text]
  • SRC-Family Kinases in Acute Myeloid Leukaemia and Mastocytosis
    cancers Review SRC-Family Kinases in Acute Myeloid Leukaemia and Mastocytosis Edwige Voisset , Fabienne Brenet , Sophie Lopez and Paulo de Sepulveda * INSERM U1068, CNRS UMR7258, Aix-Marseille Université UM105, Institute Paoli-Calmettes, CRCM—Cancer Research Center of Marseille, U1068 Marseille, France; [email protected] (E.V.); [email protected] (F.B.); [email protected] (S.L.) * Correspondence: [email protected] Received: 28 May 2020; Accepted: 19 July 2020; Published: 21 July 2020 Abstract: Protein tyrosine kinases have been recognized as important actors of cell transformation and cancer progression, since their discovery as products of viral oncogenes. SRC-family kinases (SFKs) play crucial roles in normal hematopoiesis. Not surprisingly, they are hyperactivated and are essential for membrane receptor downstream signaling in hematological malignancies such as acute myeloid leukemia (AML) and mastocytosis. The precise roles of SFKs are difficult to delineate due to the number of substrates, the functional redundancy among members, and the use of tools that are not selective. Yet, a large num ber of studies have accumulated evidence to support that SFKs are rational therapeutic targets in AML and mastocytosis. These two pathologies are regulated by two related receptor tyrosine kinases, which are well known in the field of hematology: FLT3 and KIT. FLT3 is one of the most frequently mutated genes in AML, while KIT oncogenic mutations occur in 80–90% of mastocytosis. Studies on oncogenic FLT3 and KIT signaling have shed light on specific roles for members of the SFK family. This review highlights the central roles of SFKs in AML and mastocytosis, and their interconnection with FLT3 and KIT oncoproteins.
    [Show full text]
  • Facial Cutaneo-Mucosal Venous Malformations Can Develop
    Brahami et al. Journal of Negative Results in BioMedicine (2017) 16:9 DOI 10.1186/s12952-017-0072-5 BRIEFREPORT Open Access Facial cutaneo-mucosal venous malformations can develop independently of mutation of TEK gene but may be associated with excessive expression of Src and p-Src Nabila Brahami1, Selvakumar Subramaniam2, Moudjahed Saleh Al-Ddafari1, Cecile Elkaim3, Pierre-Olivier Harmand3, Badr-Eddine Sari1,4, Gérard Lefranc5 and Mourad Aribi1* Abstract We aimed to search for mutations in the germline and somatic DNA of the TEK gene and to analyze the expression level of Src and phospho-Src (p-Src) in tumor and healthy tissues from patients with facial cutaneo-mucosal venous malformations (VMCM). Eligible patients from twelve families and thirty healthy controls were recruited respectively at the Departments of Stomatology and Oral Surgery, and Transfusion Medicine of Tlemcen University Medical Centre. Immunoblot analyses of Src and p-Src were performed after direct DNA sequencing. No somatic or germline mutations werefoundinallthe23exonsandtheir5’ and 3’ intronic flanking regions, except for one case in which a c.3025+20- 3025+22 del mutation was highlighted at the intron 15, both in the germline and somatic DNA. Additionally, elevated expression levels of Src and p-Src were observed only in the patient with such mutation. However, when normalized to β-actin, the overall relative expression levels of both Src and p-Src were significantly increased in VMCM tissues when compared to healthy tissues (for both comparisons, p <0.001). In conclusion, we confirm the outcomes of our previous work suggesting that VMCM can develop independently of mutation of the TEK gene.
    [Show full text]
  • Tyrosine Kinases As Targets for the Treatment of Rheumatoid Arthritis Christina D’Aura Swanson, Ricardo T
    REVIEWS Tyrosine kinases as targets for the treatment of rheumatoid arthritis Christina D’Aura Swanson, Ricardo T. Paniagua, Tamsin M. Lindstrom and William H. Robinson Abstract | As critical regulators of numerous cell signaling pathways, tyrosine kinases are implicated in the pathogenesis of several diseases, including rheumatoid arthritis (RA). In the absence of disease, synoviocytes produce factors that provide nutrition and lubrication for the surrounding cartilage tissue; few cellular infiltrates are seen in the synovium. In RA, however, macrophages, neutrophils, T cells and B cells infiltrate the synovium and produce cytokines, chemokines and degradative enzymes that promote inflammation and joint destruction. In addition, the synovial lining expands owing to the proliferation of synoviocytes and infiltration of inflammatory cells to form a pannus, which invades the surrounding bone and cartilage. Many of these cell responses are regulated by tyrosine kinases that operate in specific signaling pathways, and inhibition of a number of these kinases might be expected to provide benefit in RA. D’Aura Swanson, C. et al. Nat. Rev. Rheumatol. 5, 317–324 (2009); doi:10.1038/nrrheum.2009.82 Introduction Rheumatoid arthritis (RA) is an autoimmune synovitis that tyrosine kinases (RTKs) and non­receptor tyrosine kinases affects 0.5% of the population and can result in disability (non­rTKs).3 In addition to an extracellular ligand­binding owing to joint destruction.1 A number of cellular responses domain and a membrane­spanning domain, RTKs usually are thought to be involved in the pathogenesis of RA. An possess an intracellular cytoplasmic domain that contains adaptive autoimmune response mediated by T cells and a kinase core and regulatory sequences.
    [Show full text]
  • The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis
    cancers Review The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis 1, 2, , 1, Stephen P. Ducray y , Karthikraj Natarajan y z, Gavin D. Garland z, 1, , 2,3, , Suzanne D. Turner * y and Gerda Egger * y 1 Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge CB20QQ, UK 2 Department of Pathology, Medical University Vienna, 1090 Vienna, Austria 3 Ludwig Boltzmann Institute Applied Diagnostics, 1090 Vienna, Austria * Correspondence: [email protected] (S.D.T.); [email protected] (G.E.) European Research Initiative for ALK-related malignancies; www.erialcl.net. y These authors contributed equally to this work. z Received: 7 June 2019; Accepted: 23 July 2019; Published: 30 July 2019 Abstract: Anaplastic lymphoma kinase (ALK) is a tyrosine kinase involved in neuronal and gut development. Initially discovered in T cell lymphoma, ALK is frequently affected in diverse cancers by oncogenic translocations. These translocations involve different fusion partners that facilitate multimerisation and autophosphorylation of ALK, resulting in a constitutively active tyrosine kinase with oncogenic potential. ALK fusion proteins are involved in diverse cellular signalling pathways, such as Ras/extracellular signal-regulated kinase (ERK), phosphatidylinositol 3-kinase (PI3K)/Akt and Janus protein tyrosine kinase (JAK)/STAT. Furthermore, ALK is implicated in epigenetic regulation, including DNA methylation and miRNA expression, and an interaction with nuclear proteins has been described. Through these mechanisms, ALK fusion proteins enable a transcriptional programme that drives the pathogenesis of a range of ALK-related malignancies. Keywords: ALK; ALCL; NPM-ALK; EML4-ALK; NSCLC; ALK-translocation proteins; epigenetics 1. Introduction Anaplastic lymphoma kinase (ALK) was first successfully cloned in 1994 when it was reported in the context of a fusion protein in cases of anaplastic large cell lymphoma (ALCL) [1].
    [Show full text]
  • Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
    cancers Review Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy 1,2, 3,4 1 2 3, Charles Pottier * , Margaux Fresnais , Marie Gilon , Guy Jérusalem ,Rémi Longuespée y 1, and Nor Eddine Sounni y 1 Laboratory of Tumor and Development Biology, GIGA-Cancer and GIGA-I3, GIGA-Research, University Hospital of Liège, 4000 Liège, Belgium; [email protected] (M.G.); [email protected] (N.E.S.) 2 Department of Medical Oncology, University Hospital of Liège, 4000 Liège, Belgium; [email protected] 3 Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital of Heidelberg, 69120 Heidelberg, Germany; [email protected] (M.F.); [email protected] (R.L.) 4 German Cancer Consortium (DKTK)-German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany * Correspondence: [email protected] Equivalent contribution. y Received: 17 January 2020; Accepted: 16 March 2020; Published: 20 March 2020 Abstract: Receptor tyrosine kinases (RTKs) are key regulatory signaling proteins governing cancer cell growth and metastasis. During the last two decades, several molecules targeting RTKs were used in oncology as a first or second line therapy in different types of cancer. However, their effectiveness is limited by the appearance of resistance or adverse effects. In this review, we summarize the main features of RTKs and their inhibitors (RTKIs), their current use in oncology, and mechanisms of resistance. We also describe the technological advances of artificial intelligence, chemoproteomics, and microfluidics in elaborating powerful strategies that could be used in providing more efficient and selective small molecules inhibitors of RTKs.
    [Show full text]
  • Ph.D. Dissertation
    PDK-1/AKT PATHWAY AS TARGETS FOR CHEMOSENSITIZING EFFECTS DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Ping-Hui Tseng, M.S. ***** The Ohio State University 2005 Dissertation Committee: Approved by Professor Ching-Shih Chen, Advisor Professor Pui-Kai Li Adviser Graduate Program in Pharmacy Professor Charles L. Shapiro Professor Tatiana M. Oberyszyn ABSTRACT Cancer is the leading causes of human deaths all over the world. The growing understanding in cancer biology provides the researchers to develop molecularly targeted therapeutic strategies. However, the toxicity and resistance limit the applications for molecularly targeted agents. Here, we proposed that inhibiting PI3K/PDK-1/Akt signaling pathway, which is critical in controlling cell survival and proliferation, is able to enhance the therapeutic effects and overcome resistance of the current used molecularly targeted drugs. Imatinib (STI571; Gleevec), a selective bcr-abl tyrosine kinase inhibitor, is approved to treat patients with chronic myelogenous leukemia (CML). However, patients in more advanced phases of CML frequently develop resistance to the treatment. Mutations within the kinase domain for the binding of imatininb attributes as one of the major imatinib-resistant mechanisms. The effects of imatinib each alone and in combination with OSU-03012, a novel celecoxib-derived PDK-1 inhibitor, was evaluated in a panel of Bcr-Abl positive Ba/F3 cell lines without or with mutations. The IC50 values for OSU- 03012 alone were comparable, while the sensitivities to imatinib alone were differed. The combination treatment, however, caused a synergistic enhancement of apoptosis in these cells, including those that are resistant to imatinib.
    [Show full text]